ConcertAI

Overview

Industry: Healthcare AI, Real-World Evidence, Clinical Development Founded: 2017 Headquarters: Cambridge, Massachusetts (1120 Massachusetts Avenue) Employees: ~819 (as of 2024) Website: https://www.concertai.com

ConcertAI is a leading enterprise AI and real-world data (RWD) platform for life sciences and healthcare. Founded in 2017 by Dr. Jeff Elton, the company specializes in leveraging generative and agentic AI to transform clinical research, drug development, and cancer care operations. Headquartered in Cambridge with operations spanning the US, Europe, and Japan, ConcertAI serves 75% of the top 30 life sciences organizations and over 2,000 healthcare providers. The company achieved significant growth with 2024 revenues reaching $248M (up from $160M in 2023) and achieved profitability with mid-teens adjusted EBITDA margins. ConcertAI is part of SymphonyAI, a global enterprise AI platform operating under SAIGroup led by Dr. Romesh Wadhwani.

Products & Services

Patient360

• Description: The industry's most deeply curated real-world oncology dataset linking EHR, claims, genomics, social determinants of health (SDoH), and death dates. Provides 360-degree patient views with 100+ clinical variables per patient, machine-supported abstraction, and cohort augmentation capabilities. With the Foundation Medicine integration, ConcertAI now provides access to nearly 500,000 patients with linked genomic and clinical data.
• Target market: Biopharmaceutical companies, CROs, medical societies, and academic medical centers requiring RWE for drug development, clinical trial design, and regulatory submissions
• Pricing model: Enterprise SaaS with usage-based components

Precision Trials™

• Description: SaaS solution combining real-world data with generative AI agents to dynamically design, evaluate, and adapt clinical trial strategy. GenAI-driven modeling for standard of care, enrollment timelines, diversity, and site selection with embedded GenAI Copilot for real-time strategic insights.
• Target market: Clinical trial sponsors, CROs, and biopharmaceutical R&D teams
• Pricing model: Enterprise SaaS subscription

Precision360™

• Description: First population-scale generative and agentic AI-curated data solution offering detailed patient journey views with exceptional recency and low latency. Part of the newly announced Precision Suite of GenAI-native solutions supporting major Life Science functions.
• Target market: Life sciences functions requiring population-scale insights with rapid data availability
• Pricing model: Enterprise SaaS

Accelerated Clinical Trials (ACT)

• Description: Enterprise agentic AI platform launched in February 2026 that automates end-to-end clinical trial processes, integrating real-world and proprietary data with advanced AI workflows to reduce trial timelines by 10-20 months. Incorporates patient identification, site selection optimization, enrollment forecasting, and trial feasibility assessment.
• Target market: Clinical trial sponsors and CROs seeking to reduce development timelines and costs
• Pricing model: Enterprise SaaS with outcome-based pricing models under development

CARAai Platform

• Description: Multi-modal data management, predictive AI, and generative AI platform for accelerating research from translational through clinical development. Leverages multi-agentic AI development framework, proprietary multi-small language models (SLMs), and multi-large language models (LLMs) tuned for oncology insights and clinical development. Collaborative NVIDIA integration announced for 2025.
• Target market: Translational research, clinical development, and precision medicine organizations
• Pricing model: Enterprise platform licensing

Precision Insights Suite

• Description: GenAI-native solutions supporting major Life Science functions including research, development, commercial, and regulatory operations.
• Target market: Integrated life sciences organizations seeking AI-powered workflow automation across functions
• Pricing model: Enterprise SaaS suite

Real-World Data Products

• Description: Curated oncology datasets integrated with claims, genomic, and social determinants of health data, supporting rapid evidence generation across treatment, biomarkers, and outcomes across tumor types.
• Target market: Clinical researchers, health economists, and real-world evidence analysts
• Pricing model: Data subscription with usage tiers

Market Position & Industry Dynamics

Market segment: AI-powered real-world evidence and clinical development tools within oncology-focused healthcare AI

Estimated market share: 14.9% of AI in oncology market (behind Tempus at 22.4% and Paige AI at 18.7%)

TAM:

• Global AI in oncology market: $22.85B by 2033 at 25.3% CAGR (Grand View Research)
• AI-based clinical trials solutions: $7.8B by 2030, growing at 22.1% CAGR from 2024 (current $1.9B)
• Real-world evidence solutions for oncology: $4.77B by 2032 at 13.2% CAGR (from $1.38B in 2022)

SAM:

• Oncology real-world evidence segment alone: ~$1.38B current market with 13.2% CAGR growth
• Clinical trial optimization tools: ~$1.5B current market (2022 baseline)

Industry Trends:

• AI-Driven Clinical Trial Transformation: Rapid adoption of generative AI for patient matching, site selection, and enrollment optimization, reducing trial timelines by 10-20 months. Both competitors (Tempus, Flatiron) and ConcertAI racing to deploy agentic AI for end-to-end trial automation.
• Real-World Evidence Regulatory Acceptance: Increased FDA collaboration and regulatory pathways for RWE (ConcertAI has 5-year FDA collaboration agreement), driving adoption for label expansions, comparative effectiveness, and post-market surveillance.
• Data Integration and Genomic-Clinical Linking: Industry shift toward integrated datasets combining EHR, claims, genomic, and imaging data. ConcertAI's Foundation Medicine partnership and others' multi-modal integrations demonstrate this trend.
• Platform Consolidation and M&A: Significant M&A activity including Roche's 2018 acquisition of Flatiron Health for $1.9B, ConcertAI's 2023 acquisition of CancerLinQ, driving market consolidation and feature parity competition.
• Agentic AI and Multi-Modal LLM Adoption: Shift from traditional ML to autonomous AI agents and specialized LLMs for healthcare domain. ConcertAI's NVIDIA partnership and CARAai platform represent this evolution.

Key differentiators:

• Largest Clinically-Linked Oncology Dataset: Nearly 500,000 patients with integrated EHR, claims, genomic (via Foundation Medicine), and SDoH data—largest in the market as of 2026
• CancerLinQ Network Integration: Direct access to 5.5M+ multi-modal oncology RWD records from extensive clinician network acquired via 2023 CancerLinQ acquisition
• First-to-Market Agentic AI for Clinical Trials: Accelerated Clinical Trials platform (launched 2/2026) with claimed 10-20 month trial timeline reduction before competitors
• Profitability and ARR Momentum: Only major competitor demonstrating profitability (2024) with 72% ARR and consistent revenue growth (55% growth 2023-2024)
• Regulatory Pedigree: Formal 5-year collaboration with FDA (since 2021) on RWE methodologies, providing regulatory confidence advantage
• Enterprise Customer Concentration: 75% of top 30 biopharma customers, representing deep, sticky relationships with largest customers

Positioning:

ConcertAI positions itself as the "enterprise-grade real-world evidence and agentic AI partner for life sciences," emphasizing data quality, regulatory collaboration, and AI innovation for trial acceleration. Messaging focuses on outcomes (faster trials, better evidence, regulatory acceptance) rather than data volume alone. Competes on three axes: (1) data comprehensiveness and quality, (2) AI/agentic capabilities, and (3) regulatory acceptance and formality.

Leadership Team

Financials

• 2024 Revenue: $248M (up 55% from $160M in 2023)
• 2024 ARR: 72% of total revenue ($177.6M), highest ever achieved
• 2024 Profitability: Exiting FY2024 profitable with mid-teens adjusted EBITDA margins (~$37-40M estimated EBITDA)
• Funding: $300M total raised across multiple rounds
  • Series C (2024): $150M from Sixth Street Partners at $1.9B valuation
  • Series B: $150M (prior round)
  • Other investors: Declaration Partners, Maverick Ventures, AB Private Credit Investors (AllianceBernstein)
• Valuation: $1.9B (post-Series C, 2024)
• Employee Count: ~819 (2024)

Recent News & Developments

• [2026-03] ConcertAI presents CARAai Multi-LLM and Agentic AI solutions at NVIDIA GTC 2025, showcasing multi-agentic AI development framework and oncology-tuned language models
• [2026-02] ConcertAI launches Accelerated Clinical Trials (ACT) platform with claimed 10-20 month timeline reductions; launches Precision360 and Precision Insights Suite
• [2026-01] ConcertAI and Foundation Medicine announce integration of genomic and clinical data, expanding patient dataset to nearly 500,000 with linked genomic data
• [2025-01] ConcertAI presents 2024 results at J.P. Morgan Healthcare Conference: reports first year of profitability, 72% ARR, and unveils 2025-2028 AI solutions roadmap
• [2024-12] Announced collaboration with NVIDIA on translational and clinical development solutions using oncology-tuned NVIDIA NIM microservices; medical imaging expansion planned for 2025
• [2024-06] ConcerAI and NeoGenomics announce collaboration building joint hematology registry with 370,000+ patients, demonstrating linked pathology and longitudinal EHR data capabilities
• [2023-12] ConcertAI acquires CancerLinQ from ASCO; commits $250M+ to enhance data, clinical trial solutions, and DACT platform; maintains multi-year ASCO cooperation agreement
• [2023-12] CEO leadership transition: Eron Kelly appointed CEO; Dr. Jeff Elton transitions to Vice Chairman

Competitive Landscape

Direct competitors:

• Tempus AI — Market leader at 22.4% share with AI-powered clinical decision support, large multimodal oncology datasets, and genomic testing integration. IPO filed 2025. Direct competition on RWE-powered trial design and clinical analytics. Recently partnered with Flatiron (integrated Tempus genomic profiling into OncoEMR), limiting ConcertAI's positioning as superior integrator.
• Flatiron Health (Roche subsidiary) — Acquired by Roche for $1.9B (2018); operates OncoEMR with 800+ community cancer centers and 4,200+ providers. Strong EHR position and Roche R&D integration advantage. Recently partnered with Tempus, showing collaborative rather than purely competitive dynamic.
• Aetion — Real-world evidence analytics focused on regulatory-grade evidence generation and outcomes research. Primary competition on RWE methodology and regulatory pathways.
• TriNetX — Private equity-backed Cambridge, MA-based competitor focused on oncology health outcomes and clinical trial efficiency research via healthcare provider network.
• Verana Health — Real-world evidence platform competitor with strong surgical and oncology data assets.
• Paige AI — Holds 18.7% market share driven by FDA-cleared AI pathology solutions and cancer center partnerships; competes less directly on RWE for drug development but increasingly on clinical decision support.

Competitive advantages:

• Data Comprehensiveness: Nearly 500,000 patients with integrated EHR, claims, genomic, and SDoH data (largest in market post-Foundation Medicine deal)
• CancerLinQ Network Access: Direct connection to extensive oncology practice network acquired in 2023 acquisition
• Agentic AI Leadership: First major player to market with autonomous AI agents for trial design and patient matching (ACT platform, Feb 2026)
• Regulatory Credibility: Formal 5-year FDA collaboration and RWE methodological development credibility
• Profitability Position: Only major competitor demonstrating path to profitability with positive EBITDA (2024), providing financial stability vs. burn-focused competitors
• Enterprise Incumbent Status: 75% of top 30 biopharma already deployed at scale, creating switching costs and upsell vectors

Competitive vulnerabilities:

• Market Share Behind Tempus: Trails Tempus (22.4%) and Paige AI (18.7%) at 14.9% share, despite larger dataset. Suggests data quality/comprehensiveness alone doesn't drive adoption.
• Slower Genomic Integration than Tempus: Tempus owns genomic testing capability (Tempus xF, xT, xD); ConcertAI relies on partnership with Foundation Medicine, giving Tempus vertical integration advantage.
• Organizational Complexity: CEO transition (Kelly from Inovalon) may indicate integration challenges from rapid acquisition (CancerLinQ) or organizational scaling issues. Employee Glassdoor reviews cite poor upper management visibility, frequent restructuring.
• Flatiron's Health System Entrenchment: Flatiron's OncoEMR position in 800+ community cancer centers creates switching costs and direct patient care workflow lock-in that RWD platforms cannot replicate.
• Talent and Culture Concerns: Glassdoor rating of 3.4/5 with employee concerns about frequent restructuring, overseas outsourcing, and upper management transparency issues. High employee churn risk during rapid integration period.
• Product Fragmentation: Multiple product lines (Patient360, Precision Trials, CARAai, ACT) may create complexity vs. more integrated competitor offerings; unclear if customers adopt multiple products or single best-of-breed point solutions.

Strategic Assessment

Strengths

• Largest Integrated Oncology Dataset: Nearly 500,000 patients with EHR, claims, genomic (Foundation Medicine), and SDoH—provides unmatched scope for evidence generation and AI training. Enables regulatory submissions, biomarker discovery, and treatment insights impossible with smaller datasets. Justifies premium pricing for biopharma customers.
• Agentic AI Leadership and Innovation Velocity: ACT platform (Feb 2026) with claimed 10-20 month trial timeline reductions positions ConcertAI ahead of competitors in autonomous AI application. NVIDIA partnership and CARAai multi-LLM framework demonstrate continued R&D momentum in cutting-edge AI domains (Gen AI, agentic systems).
• Profitability and Financial Stability: Only major competitor with demonstrated profitability (2024, mid-teens EBITDA margins) and sustainable unit economics (72% ARR, $248M revenue on 819 employees = $303k revenue/employee). Financial strength enables sustained R&D investment and M&A capability without VC financing pressure.
• Enterprise Customer Concentration and Stickiness: 75% of top 30 biopharma represent deep, sticky relationships with highest-value customers. Multi-product deployment (data + trials + insights) and mission-critical role in drug development create switching costs and high LTV.
• Regulatory Credibility: 5-year formal FDA collaboration on RWE methodologies (since 2021) and regulatory-grade post-approval study capabilities provide unique credibility for regulatory submissions and label expansions. Differentiates vs. pure data/tech plays.

Weaknesses

• Market Share Behind Competitors Despite Data Advantage: 14.9% market share vs. Tempus (22.4%) and Paige AI (18.7%) despite largest dataset indicates data comprehensiveness alone insufficient for market leadership. Suggests either product/UX gaps, sales/go-to-market weakness, or customer preferences for specialized solutions (Tempus genomics, Paige pathology).
• Organizational Culture and Talent Retention Issues: Glassdoor 3.4/5 rating with employee complaints about frequent restructuring, leadership transparency, overseas outsourcing of data/operations, and non-transparent terminations. CancerLinQ integration (2023) and new CEO (Kelly, 2025) may exacerbate organizational disruption. High-impact roles (data scientists, engineers) critical to AI development may experience churn.
• CEO Transition and Leadership Continuity Risk: Eron Kelly (ex-Inovalon) brings SaaS scaling expertise but represents loss of founder visionary (Elton now Vice Chairman). Kelly's AWS/Microsoft background emphasizes operational scaling over domain expertise. Transition timing coincides with rapid product launches (ACT, Precision360), creating execution risk if organizational alignment deteriorates.
• Reliance on Partnership for Genomic Data: Foundation Medicine integration crucial for genomic comprehensiveness, but dependency creates vulnerability to pricing, data access, or strategic direction changes. Tempus owns genomic capabilities; Flatiron/Roche benefits from Roche's genomic portfolio. ConcertAI lacks vertically integrated genomic moat.
• Product Portfolio Fragmentation: Multiple product suites (Patient360, Precision Trials, CARAai, ACT, Precision360, Precision Insights Suite) create internal complexity, sales confusion, and unclear upgrade/upsell pathways. Competitor offerings more unified; fragmentation may dilute focus and customer adoption.
• Data Quality Concerns at Scale: Employee reviews cite "quality sacrificed for quick, cheap data by overseas employees with very little medical background," suggesting potential data accuracy/completeness issues at scale. In regulatory-grade evidence generation, data quality is paramount; reputational damage from poor data could undermine FDA credibility.

Opportunities

• Clinical Trial Acceleration as Industry Standard: FDA and industry increasing focus on trial timeline reduction and patient diversity. ConcertAI's ACT platform with 10-20 month reductions directly addresses $5B+ addressable opportunity in trial acceleration. Early market leadership could establish de facto standard, creating network effects and lock-in. Potential to expand ACT from oncology to other therapeutic areas (cardiology, immunology) with $5B+ TAM each.
• Regulatory Approval of RWE for Primary Evidence: FDA increasingly accepting RWE for primary efficacy endpoints and label expansions (shift from post-market use). ConcertAI's FDA collaboration positions it to capture this expanding $2-3B market as regulatory pathways formalize. Opportunity to become trusted regulatory partner for 50%+ of biopharma RWE submissions.
• Precision Medicine and Biomarker Discovery at Scale: Integrated genomic-clinical dataset enables biomarker discovery, patient stratification, and precision oncology evidence generation at scale. Multi-tumor oncology dataset with 500k+ patients supports discovery of rare biomarker associations and companion diagnostic development. Potential to expand into precision cardiology, immunology with similar dataset building.
• International Market Expansion: Current presence in US, Europe, Japan but limited penetration in Asian markets (China, South Korea, India) with large pharma R&D bases. CARAai and Precision Trials platforms adaptable to non-US healthcare systems. Potential $1B+ TAM in emerging pharma markets with limited existing competition.
• AI-Powered Commercial Acceleration and Launch Support: Beyond clinical development, real-world evidence increasingly used for patient identification, payer negotiation, and launch optimization. ConcertAI could extend Precision360 and Insights Suite into post-launch commercial support, addressing $3B+ TAM in commercial analytics. Pharma customers already using Patient360; upsell motion to commercial teams straightforward.
• Medical Device and Diagnostic Integration: CARAai platform's multi-modal capabilities could expand to device outcomes, imaging analytics, and diagnostic test integration. Partnerships with device manufacturers (e.g., Boston Scientific, Abbott) could create adjacent $1-2B TAM. Medical device trials increasingly use RWE for market access.

Threats

• Tempus IPO and Capital Advantage: Tempus filed S-1 (2025 timeframe) with larger market cap and public capital access. Post-IPO, Tempus will have capital advantage for M&A, R&D, and international expansion. Tempus's genomic integration, larger market share (22.4%), and vertical integration present direct threat to ConcertAI's data moat and AI advantage. Tempus could acquire remaining competitors (Aetion, TriNetX) and consolidate market.
• Flatiron-Roche Integrated Advantage: Flatiron's 800+ community cancer centers and 4,200+ providers embedded in Roche's R&D workflow creates unique workflow integration and data advantage. Recent Tempus partnership (genomic integration into OncoEMR) shows Flatiron expanding beyond RWE into precision medicine. Roche's pharma portfolio ($60B+ annual pharma revenue) provides built-in customer base, pricing power, and M&A resources exceeding ConcertAI's.
• Data Privacy and Regulatory Headwinds: Increasing state-level healthcare privacy regulations (Illinois BIPA, California CCPA), HIPAA audit scrutiny, and international GDPR complexity threaten data comprehensiveness and multinational expansion. Any major breach or regulatory action could undermine ConcertAI's regulatory credibility and FDA partnership. Competitors with smaller datasets less exposed to privacy risk.
• AI Model Commoditization and Open-Source LLM Competition: Rapid advancement in open-source LLMs (Meta Llama 3, Mistral) and accessible fine-tuning tools reduces moat around proprietary CARAai LLMs. ConcertAI's AI advantage depends on specialized oncology training data and fine-tuning—if competitors acquire similar data and apply commodity LLMs, AI differentiation erodes. OpenAI/Anthropic could enter market with foundational models + plugin architectures.
• Economic Downturn and Pharma R&D Contraction: Pharma industry facing patent cliffs and R&D productivity challenges; economic downturn could reduce biopharma R&D budgets, directly impacting ConcertAI's enterprise customers. 75% customer concentration in top 30 pharma creates vulnerability to sector-wide budget cuts. Smaller biotech customers (lower ACV) more price-sensitive and at churn risk.
• Competitive Feature Parity and Commoditization: Trial design, patient matching, and site selection capabilities spreading across CRO platforms (Covance, IQVIA, Syneos), EHR vendors, and analytics platforms. As features commoditize, ConcertAI's premium pricing ($10M+ ACV for top customers) at risk. Margin compression from competitive dynamics already visible in market share losses (22.4% Tempus vs. 14.9% ConcertAI despite larger dataset).

Public Sentiment

Overall sentiment: Mixed — Positive on product innovation and customer value delivery; negative on organizational culture, execution stability, and employee retention

Customer sentiment:

Strong and positive on product value delivery. Enterprise customers (75% of top 30 pharma) report significant trial acceleration and evidence generation benefits; many are multi-product adopters (Patient360 + Precision Trials + CARAai). Favorable reputation at industry conferences (ASCO 2024, J.P. Morgan Healthcare 2025). No significant customer churn data publicly available, suggesting stickiness despite competitive pressure. Limited public reviews on G2 or independent review platforms—data primarily available through industry analyst coverage and case studies.

Employee sentiment:

Glassdoor rating of 3.4/5 (as of research date) with mixed employee feedback. Positive themes: (1) Interesting mission in healthcare/oncology AI, (2) Smart, talented colleagues, (3) Supportive direct management, (4) Flexible work/life balance. Negative themes: (1) Frequent restructuring and organizational instability, (2) Leadership lacks transparency and vision beyond direct managers, (3) Quick to terminate long-term employees for offshore outsourcing (particularly data operations to India), (4) Quality sacrificed for cost in data operations, (5) Siloed organization limiting cross-functional collaboration, (6) Non-transparent layoff and termination processes. Recent CEO transition (Kelly, 2025) and CancerLinQ integration (2023) likely drove restructuring concerns. High attrition risk in data science and engineering roles.

Analyst sentiment:

Positive from industry analysts and market research firms. Grand View Research, Emergen Research, and Mordor Intelligence rate ConcertAI as key player in AI oncology and RWE markets with strong positioning. Analysts cite data comprehensiveness, FDA collaboration, and agentic AI leadership as competitive strengths. Gartner and Forrester coverage emphasizes ConcertAI's enterprise focus and regulatory credibility. No negative analyst downgrades or competitive positioning concerns published; analysts generally rate ConcertAI favorably vs. pure-play competitors. IPO markets view positively (Sixth Street $1.9B valuation validates investor confidence).

Sentiment Drivers

Growth Vectors

Stated strategy:

ConcertAI's 2025-2028 roadmap (announced 1/2025) focuses on: (1) AI Innovation Leadership — expanding agentic AI and multi-LLM capabilities (CARAai, ACT), (2) Data Comprehensiveness — integrating genomic, imaging, and clinical data at population scale, (3) Use Case Expansion — moving from trial design/optimization to clinical decision support, commercial acceleration, and precision medicine, (4) Platform Consolidation — unifying Precision Suite, CARAai, ACT, and Patient360 into integrated customer experience, (5) International Expansion — extending US-proven solutions to European and Asian markets, (6) Regulatory Moat Building — deepening FDA collaboration and establishing RWE standards.

Existing Market Expansion

• Vertical Integration within Biopharma Customers: Top 30 biopharma currently using 1-2 ConcertAI products (Patient360, Precision Trials); expansion to 3-4 products per customer (CARAai, Precision360, Insights Suite) represents 3-4x revenue opportunity per existing customer without new sales cycles. Upsell motion low-friction given existing relationships and data integration.
• Therapeutic Area Expansion: Currently oncology-focused; expansion to cardiology, immunology, ophthalmology with distinct datasets and use cases. Each therapeutic area addressable $1-2B TAM with similar product portfolio approach.
• Segment Expansion within Life Sciences: Currently focused on drug development; expansion to CRO services, medical device, diagnostics, and payer analytics. IQVIA, Covance, Syneos already expanding into RWE platforms; ConcertAI could serve as underlying data/AI platform for CRO expansion.

New Market Opportunities

• Clinical Decision Support and Precision Oncology: Shift from drug development RWE to clinical treatment decision support (identifying best therapy for individual patient based on genomic/phenotypic data). Precision360 and CARAai platforms positioned for this; addressable market $2-3B in US alone.
• Post-Launch Commercial Acceleration: Use real-world evidence for patient identification, payer negotiation, outcomes tracking, and launch optimization. Significant $3B+ TAM in commercial analytics largely untapped by ConcertAI. Natural extension of Patient360 and Insights Suite.
• International Market Expansion: Asia-Pacific, European, and emerging markets have growing pharma R&D bases with limited RWE competition. CARAai and Precision Trials adaptable to regional healthcare data systems. $1-2B TAM in high-growth markets (China, India, South Korea).
• Medical Device and Diagnostic Outcomes: Device manufacturers increasingly using RWE for market access and post-market surveillance. ConcertAI's multi-modal data integration (including imaging via TeraRecon) positions it for device outcomes analytics. $1-2B TAM in device outcomes.
• Precision Medicine and Biomarker Discovery Licensing: Monetize biomarker discoveries and precision medicine insights through licensing to diagnostics companies, therapeutic companies, or precision medicine platforms (e.g., Foundation Medicine, Natera). $500M-1B licensing TAM.

Growth Vector Assessment

Discovered Entities

People

• Eron Kelly | Chief Executive Officer | https://www.linkedin.com/in/eron-kelly/ (implied, typical LinkedIn pattern)
• Dr. Jeff Elton | Vice Chairman, Founding CEO | https://www.linkedin.com/in/jelton/
• Dr. Romesh Wadhwani | Executive Chairman | https://www.linkedin.com/in/romesh-wadhwani/
• Ronan Brown | Chief Operating Officer | [Title known, URL not publicly available]
• Claudio D'Ambrosio | Chief Revenue Officer | [Title known, URL not publicly available]
• Lauren Gordon | Chief People Officer | [Title known, URL not publicly available]

Competitors

• Tempus AI | AI-powered precision medicine and clinical decision support platform with integrated genomic testing; market leader at 22.4% share in AI oncology; filed S-1 for IPO (2025); competitive on RWE-driven trial design and genomic integration; recently partnered with Flatiron (Tempus genomic profiling integration into OncoEMR)
• Flatiron Health (Roche subsidiary) | Acquired by Roche (2018, $1.9B); operates OncoEMR EHR platform with 800+ community cancer centers and 4,200+ providers; competes on clinical trial optimization, real-world evidence, and oncology care workflow integration; Roche vertical integration advantage (pharma portfolio, genomics)
• Aetion | Real-world evidence analytics platform focused on regulatory-grade evidence generation, comparative effectiveness, and outcomes research; competes directly on RWE methodology and FDA regulatory pathway acceptance
• TriNetX | Private equity-backed Cambridge, MA-based healthcare network platform focused on oncology outcomes and clinical trial matching research; competes on trial optimization and RWE network effects
• Verana Health | Real-world evidence platform with surgical and oncology data assets; competes on clinical trial design and outcomes research
• Paige AI | AI pathology solutions with 18.7% market share in AI oncology; FDA-cleared AI diagnostic tools and cancer center partnerships; competes less directly on RWE for drug development but increasingly on clinical decision support and digital pathology
• IQVIA | Global CRO and data analytics giant with RWE platform; competes on trial design, CRO services integration, and global reach; larger but less specialized in oncology RWE than ConcertAI
• Syapse | Precision medicine analytics platform enabling care coordination and clinical trial matching; competes on precision oncology insights and trial enrollment
• Unlearn.AI | AI synthetic control arm generation for clinical trials; competes specifically on trial design acceleration and patient matching innovation